Search research articles
Contact Us
Filters
Showing results (671-680 of 691) with videos related to
Page
of 70
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K E Francis, S I Kim, M Friedlander, et al.
Nature
|
April 21, 2016
Polar metals by geometric design
T H Kim, D Puggioni, Y Yuan, et al.
The Journal of Hospital Infection
|
August 24, 2020
Environmental contamination in the isolation rooms of COVID-19 patients with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy
J Y Ahn, S An, Y Sohn, et al.
Genes, Brain, and Behavior
|
July 19, 2011
Neuregulin 3 does not confer risk for schizophrenia and smooth pursuit eye movement abnormality in a Korean population
C-F Pasaje, J-S Bae, B-L Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J S Frenel, J W Kim, N Aryal, et al.
British Journal of Cancer
|
December 21, 2013
Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study
S Y Ryu, M H Kim, B H Nam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
S Y Ryu, W Deng, K Albuquerque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
A Karam, J A Ledermann, J-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2018
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Y-K Kang, M-H Ryu, S H Park, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
Page
of 70
Search research articles
Search
Showing results (671-680 of 691) with videos related to
Sort By:
Page
of 70
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K E Francis, S I Kim, M Friedlander, et al.
Nature
|
April 21, 2016
Polar metals by geometric design
T H Kim, D Puggioni, Y Yuan, et al.
The Journal of Hospital Infection
|
August 24, 2020
Environmental contamination in the isolation rooms of COVID-19 patients with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy
J Y Ahn, S An, Y Sohn, et al.
Genes, Brain, and Behavior
|
July 19, 2011
Neuregulin 3 does not confer risk for schizophrenia and smooth pursuit eye movement abnormality in a Korean population
C-F Pasaje, J-S Bae, B-L Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J S Frenel, J W Kim, N Aryal, et al.
British Journal of Cancer
|
December 21, 2013
Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study
S Y Ryu, M H Kim, B H Nam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
S Y Ryu, W Deng, K Albuquerque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
A Karam, J A Ledermann, J-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2018
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Y-K Kang, M-H Ryu, S H Park, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
Page
of 70